Key Takeaways Cagrilintide is a long-acting amylin analogue typically dosed at 2.4 mg weekly in clinical trials, working through distinct pathways from GLP-1 receptor agonists Tirzepatide follows a gradual escalation protocol from 2.5 mg to 15 mg weekly as a dual GIP/GLP-1 receptor agonist No approved combination of cagrilintide with tirzepatide currently exists, though the concept represents theoretical triple-pathway metabolic modulation Gastrointestinal side effects require careful monitoring when considering any combination of these peptides due to overlapping mechanisms Clinical evidence for cagrilintide combinations exists primarily with semaglutide, showing 15-17% body weight reductions in phase 3 trials Understanding Cagrilintide: The Amylin Analogue Cagrilintide represents a breakthrough in amylin-based therapeutics, developed by Novo Nordisk as a long-acting analogue of the naturally occurring hormone amylin[1]

NAD supplements can also be taken to the next level by pairing them with other healthy aging nutrients like resveratrol, which protects against oxidative stress and supports cardiovascular, brain, and metabolic health
To assess enhanced analgesia, the first assessment at time "0" was preceded by the application of morphine or saline 30 min before (time "-30 min"), by the application of haloperidol or saline 20 min (time "-20 min"), and, lastly, by the application of gastric pentadecapeptide BPC 157 or naloxone or saline (5 ml/kg i.p.) 10 min (time "-10 min")
doi: 10.1016/J.RVSC.2011.11.008 126 TriantaphyllopoulosK